Immunomedics (IMMU) 10-Q/A 19 Mar 14 2014 Q1 Quarterly report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Sep. 30, 2013	Nov. 01, 2013
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q/A	'
Amendment Flag	'true	'
Amendment Description	'Immunomedics, Inc. (“Immunomedics”) is filing this Amendment No. 1 of Form 10-Q/A (“Form 10-Q/A”) to amend its quarterly report on Form 10-Q for the three-month period ended September 30, 2013 as filed with the Securities and Exchange Commission (the “Commission”) on November 4, 2013 (the “Original Quarterly Filing”). This Form 10-Q/A discloses and discusses the impact and effect of a correction of an immaterial error of the previously filed financial statements for the three-month period ended September 30, 2013; and amends Items 1, 2 and 4 of Part I of the Quarterly Report on Form 10-Q of the Original Filing. We are filing this amendment to correct an immaterial error in its accounting for clinical trial expense and accrued liabilities and to expand the disclosures regarding its licensing agreement with UCB, S.A. and research and development accounting policy. The total amount of the overstatement of the accrued liability for clinical trials as of June 30, 2013 was determined to be $3.2 million. Due to this error, the Company’s operating expenses and accrued liabilities were immaterially overstated during each of the fiscal years 2008-2013 as noted in Note 11: Correction of Immaterial Error. The Company has also concluded that as a result of this immaterial error there was a material weakness in internal control over financial reporting as of June 30, 2013 and September 30, 2013. The Company assessed the materiality of this error for each quarterly and annual period in accordance with Staff Accounting Bulletin No. 99, Materiality, and determined that the error was immaterial to each of the previously reported periods. However, the Company determined that the adjustment to correct the error in fiscal 2014 would be material. Accordingly, the Company has revised its consolidated balance sheet as of September 30, 2013 and its consolidated statement of comprehensive loss for the three month period ended September 30, 2013. This First Amended Quarterly Report on Form 10-Q/A for the three-month period ended September 30, 2013 (the “Amended Report”) amends only those items of the previously filed Quarterly Report on Form 10-Q which have been affected by the immaterial error. In order to preserve the nature and character of the disclosures set forth in such items as originally filed, no attempt has been made in this amendment (i) to modify or update such disclosures except as required to reflect the effects from the correction of the immaterial error or (ii) to make revisions to the Notes to the Unaudited Condensed Consolidated Financial Statements, except for those which are required by or result of the effects of the correction of the immaterial error, as well as the expanded disclosures for the UCB, S.A. licensing agreement and the research and development accounting policy. For additional information regarding the error in clinical trial accruals and expenses, see Note 11 to the Condensed Consolidated Financial Statements included in Part I – Item 1. For additional information regarding the expanded disclosures concerning its licensing agreement with UCB, S.A. and the research and development accounting policy, see Notes 8 and 1, respectively to the Condensed Consolidated Financial Statements included in Part I – Item 1. No other information contained in the previously filed Form 10-Q for the year ended September 30, 2013 has been updated or amended. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, the certifications pursuant to Section 302 and Section 906 of the Sarbanes-Oxley Act of 2002, filed and furnished, respectively, as exhibits to the Original Filing have been re-executed and re-filed as of the date of this Amended Report and are included as exhibits hereto.	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'IMMU	'
Entity Registrant Name	'IMMUNOMEDICS INC	'
Entity Central Index Key	'0000722830	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	83,134,280

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Jun. 30, 2013
ASSETS	'	'
Cash and cash equivalents	$14,643,050	$41,326,000
Marketable securities	20,082,913	'
Accounts receivable, net of allowance for doubtful accounts of $70,418 at September 30, 2013 and $49,265 at June 30, 2013	399,889	622,830
Inventory	973,642	1,030,480
Other receivables	938,230	172,468
Prepaid expenses	1,227,265	432,660
Other current assets	241,568	1,631,172
Total current assets	38,506,557	45,215,610
Property and equipment, net of accumulated depreciation of $26,900,669 and $26,743,481 at September 30, 2013 and June 30, 2013, respectively	2,074,487	2,086,911
Value of life insurance policies	599,082	594,832
Other long-term assets	30,000	30,000
Total Assets	41,210,126	47,927,353
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'
Accounts payable and accrued expenses	3,713,513	3,950,866
Deferred revenues	264,543	2,780,309
Total current liabilities	3,978,056	6,731,175
Other liabilities	1,425,607	1,400,728
Commitments and Contingencies	'	'
Stockholders' Equity:	'	'
Preferred stock, $0.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at September 30, 2013 and June 30, 2013	'	'
Common stock, $0.01 par value; authorized 135,000,000 shares; issued 83,153,505 shares and outstanding 83,118,780 shares at September 30, 2013; and issued 82,841,123 shares and 82,806,398 shares outstanding at June 30, 2013	831,534	828,411
Capital contributed in excess of par	266,855,074	265,688,408
Treasury stock, at cost, 34,725 shares at September 30, 2013 and at June 30, 2013	-458,370	-458,370
Accumulated deficit	-231,240,775	-226,039,812
Accumulated other comprehensive income	229,237	161,830
Total Immunomedics, Inc. stockholders' equity	36,216,700	40,180,467
Noncontrolling interest in subsidiary	-410,237	-385,017
Total stockholders' equity	35,806,463	39,795,450
Total Liabilities and Stockholders' Equity	$41,210,126	$47,927,353

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Jun. 30, 2013
Statement Of Financial Position [Abstract]	'	'
Accounts receivable, allowance for doubtful accounts	$70,418	$49,265
Property and equipment, accumulated depreciation	$26,900,669	$26,743,481
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	135,000,000	135,000,000
Common stock, shares issued	83,153,505	82,841,123
Common stock, shares outstanding	83,118,780	82,806,398
Treasury stock, shares	34,725	34,725

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Revenues:	'	'
License fee and other revenues	$4,623,333	'
Product sales	559,023	733,187
Research and development	315,465	318,231
Total revenues	5,497,821	1,051,418
Costs and Expenses:	'	'
Costs of goods sold	77,199	96,431
Cost of license fee and other revenues	1,189,170	'
Research and development	7,514,094	6,793,922
Sales and marketing	218,032	204,392
General and administrative	1,732,671	1,272,705
Total costs and expenses	10,731,166	8,367,450
Operating loss	-5,233,345	-7,316,032
Interest and other income, net	6,211	139,179
Foreign currency transaction gain	5,452	29,705
Loss before income tax expense	-5,221,682	-7,147,148
Income tax expense	-4,501	-19,669
Net loss	-5,226,183	-7,166,817
Less net loss attributable to noncontrolling interest	-25,220	-25,932
Net loss attributable to Immunomedics, Inc. stockholders.	-5,200,963	-7,140,885
Loss per common share attributable to Immunomedics, Inc. stockholders, (basic and diluted)	($0.06)	($0.09)
Weighted average shares used to calculate loss per common share, (basic and diluted)	82,947,124	75,610,238
Other comprehensive income (loss), net of tax:	'	'
Foreign currency translation adjustments	72,367	60,146
Unrealized losses on available-for-sale securities	-4,960	'
Other comprehensive income	67,407	60,146
Comprehensive loss	-5,158,776	-7,106,671
Less comprehensive loss attributed to noncontrolling interest	-25,220	-25,932
Net comprehensive loss attributable to Immunomedics, Inc.	($5,133,556)	($7,080,739)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows used in operating activities:	'	'
Net loss	($5,226,183)	($7,166,817)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	157,188	239,285
Amortization of deferred revenue	-2,515,766	'
Gains from insurance claim for equipment	'	-137,714
Increase in allowance for doubtful accounts	21,153	14,241
Non-cash expense related to stock compensation	418,548	463,115
Non-cash increase in value of life insurance policy	-4,250	-4,350
Amortization of deferred rent	24,879	24,879
Changes in other operating assets and liabilities	-139,274	-820,723
Net cash used in operating activities	-7,263,705	-7,388,084
Cash flows (used in) provided by investing activities:	'	'
Purchase of marketable securities	-20,082,913	'
Purchases of property and equipment	-144,764	-97,721
Proceeds from insurance claim for equipment	'	137,714
Net cash (used in) provided by investing activities	-20,227,677	39,993
Cash flows provided by (used in) financing activities:	'	'
Exercise of stock options	910,677	59,071
Payments for stock plan activity	-159,436	-138,029
Net cash provided by (used in) financing activities	751,241	-78,958
Effect of changes in exchange rates on cash and cash equivalents	57,191	109,271
Net decrease in cash and cash equivalents	-26,682,950	-7,317,778
Cash and cash equivalents, beginning of period	41,326,000	32,838,096
Cash and cash equivalents, end of period	$14,643,050	$25,520,318

Business_Overview_and_Basis_of

Business Overview and Basis of Presentation	3 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Business Overview and Basis of Presentation	'
	1. Business Overview and Basis of Presentation
	Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. The Company has developed a number of advanced proprietary technologies that allows it to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, the Company has built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. The Company also manufactures and commercializes its LeukoScan® product in territories where regulatory approvals have previously been granted. The Company has two foreign subsidiaries, Immunomedics B.V. in The Netherlands and Immunomedics GmbH in Darmstadt, Germany, to assist the Company in managing sales efforts and coordinating clinical trials in Europe. In addition, included in the accompanying condensed financial statements is the majority-owned subsidiary, IBC Pharmaceuticals, Inc. (“IBC”), which has been working since 1999 on the development of novel cancer radiotherapeutics using patented pre-targeting technologies with proprietary, bispecific antibodies.
	The accompanying unaudited condensed consolidated financial statements of Immunomedics, which incorporate our subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Regulation S-X. Accordingly, the statements do not include all of the information and footnotes required by GAAP for complete annual financial statements. With respect to the financial information for the interim periods included in this Quarterly Report on Form 10-Q/A, which is unaudited, management believes that all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of the results for such interim periods have been included. The Company has reclassified prior period amounts to conform to the current period presentation. Operating results for the three-month period ended September 30, 2013 are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2014, or any other period.
	Immunomedics is subject to significant risks and uncertainties, including, without limitation, the risk that the Company may be unable to successfully obtain financing for product development; the Company’s inability to further identify, develop and achieve commercial success for new products and technologies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that the Company may be unable to secure regulatory approval of and market our drug candidates; the Company’s dependence upon pharmaceutical and biotechnology collaborations; the levels and timing of payments under our collaborative agreements, if any; uncertainties about the Company’s ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development or regulatory approval of competing products; the Company’s ability to protect its proprietary technologies; patent-infringement claims; and risks of new, changing and competitive technologies and regulations in the United States and internationally.
	As of September 30, 2013, the Company has $34.7 million of cash, cash equivalents and marketable securities. Based on the Company’s expected cash utilization rate, the Company believes it will have sufficient funds to continue its operations and research and development programs for at least the next twelve months. Cash requirements in fiscal year 2014 are expected to be in the $24.0 – $26.0 million range, which includes expenses related to the Company’s ongoing Antibody Drug Conjugate (ADC) programs and certain expenses to initiate the Company’s anticipated clivatuzumab tetraxetan Phase III clinical trial for the treatment of patients with pancreatic cancer. The Phase Ib clinical trial of clivatuzumab tetraxetan in patients with advanced pancreatic cancer was completed during the 2013 fiscal year. Based on the results of such trial, the Company decided to proceed with a Phase III clinical trial. The Company will provide further guidance regarding cash flow requirements once the full Phase III Trial estimated expenses have been determined. The Company recognizes that this trial will require additional funding. There can be no assurances that financing will be available when needed on terms acceptable to it, if at all. If the Company were unable to raise capital on acceptable terms, its ability to continue its business would be materially and adversely affected. Furthermore, the terms of any such debt or equity financing may include covenants which may limit the Company’s future ability to manage the business. At the present time, the Company is unable to determine whether any of these future activities will be successful and, if so, the terms and timing of any definitive agreements.
	The Company expects research and development activities to continue to expand over time and it does not believe it will have adequate cash to continue to conduct development of product candidates in its pipeline according to its long-term corporate strategy. As a result, the Company, in the future, will continue to require additional financial resources in order to conduct its research and development programs, clinical trials of product candidates and regulatory filings.
	Since its inception in 1982, Immunomedics’ principal sources of funds have been the private and public sale of equity and debt securities and revenues from licensing agreements, which could provide up-front and milestone payments, as well as funding of development costs and other licensing possibilities. The Company’s ability to raise capital through public and private debt or equity financings may be negatively impacted by the current weak economy. There can be no assurances that financings will be available when needed with acceptable terms to it, if at all. If the Company were unable to raise capital on acceptable terms, its ability to continue its business would be materially and adversely affected. Furthermore, the terms of any such debt or equity financing may include covenants which may limit the Company’s future ability to manage the business. At the present time, the Company is unable to determine whether any of these future activities will be successful and, if so, the terms and timing of any definitive agreements.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	These unaudited condensed consolidated interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2013. The Company adheres to the same accounting policies in preparation of its interim financial statements.
	Principles of Consolidation and Presentation
	The condensed consolidated financial statements include the accounts of Immunomedics and its subsidiaries. Noncontrolling interests in consolidated subsidiaries in the condensed consolidated balance sheets represent minority stockholders’ proportionate share of the equity (deficit) in such subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
	Revenue Recognition
	The Company has accounted for revenue arrangements that include multiple deliverables as a separate unit of accounting if: a) the delivered item has value to the customer on a standalone basis, and b) the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered items is considered probable and substantially in the control of the vendor, in accordance with the accounting standard for multiple-element arrangements. If these criteria are not met, the revenue elements must be considered a single unit of accounting for purposes of revenue recognition. The Company allocates revenue consideration, excluding contingent consideration, based on the relative selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Relative selling prices are determined using vendor specific objective evidence, if it exists; otherwise third-party evidence or the Company’s best estimate of selling price is used for each deliverable.
	Payments received under contracts to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Payments received in advance that are related to future performance are deferred and recognized as revenue when the research projects are performed or the product is delivered. Upfront nonrefundable fees associated with license and development agreements where the Company has continuing obligations in the agreement are recorded as deferred revenue and recognized over the estimated service period. If the estimated service period is subsequently modified, the period over which the upfront fee is recognized is modified accordingly on a prospective basis.
	In order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards (“FASB”) guidance on the milestone method of revenue recognition at the inception of a collaboration agreement. The criteria requires that (i) the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company’s activities to achieve the milestone, (ii) the milestone be related to past performance, and (iii) the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met, then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved. Royalties are recognized as earned in accordance with the terms of various research and collaboration agreements.
	Revenue from the sale of diagnostic products is recorded when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. Allowances, if any, are established for uncollectible amounts, estimated product returns and discounts. Since allowances are recorded based on management’s estimates, actual amounts may be different in the future.
	Research and Development Costs
	Research and development costs are expensed as incurred. Costs incurred for clinical trials for patients and investigators are expensed as services are performed in accordance with the agreements in place with the institutions.
	Manufacturing Costs
	Manufacturing costs incurred in relation to the development of materials produced in order to fulfill contractual obligations are capitalized and are recorded in other current assets until the product is delivered in accordance with the terms of the agreement. These manufacturing costs are classified as cost of license fee and other revenues when the research contractual obligations have been completed.
	Financial Instruments
	The carrying amounts of cash and cash equivalents, other current assets and current liabilities approximate fair value due to the short-term maturity of these instruments. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Investments in marketable securities are available-for-sale to fund operations. The portfolio at September 30, 2013 primarily consists of corporate debt securities and municipal bonds.
	Estimated Fair Value of Financial Instruments
	The Company has categorized its financial assets, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. The Company does not have any financial liabilities that are required to be measured at fair value on a recurring basis. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
	Financial assets recorded on the condensed consolidated balance sheets as of September 30, 2013 and June 30, 2013 are categorized based on the inputs to the valuation techniques as follows (in thousands):
		•		Level 1 – Financial assets whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the company has the ability to access at the measurement date (examples include active exchange-traded equity securities and most U.S. Government and agency securities).
		•		Level 2 – Financial assets whose value are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.
		•		Level 3 – Financial assets whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset.
			($ in thousands)
	September 30, 2013		Level 1		Level 2		Level 3		Total
	Money Market Funds		$	11,144	$	—	$	—	$	11,144
	Marketable Securities			20,083		—		—		20,083
	Total		$	31,227	$	—	$	—	$	31,227
	June 30, 2013		Level 1		Level 2		Level 3		Total
	Money Market Funds		$	38,327	$	—	$	—	$	38,327
	Total		$	38,327	$	—	$	—	$	38,327
	The money market funds noted above are included in cash and cash equivalents.
	Reimbursement of Research & Development Costs
	Research and development costs that are reimbursable under collaboration agreements are included as a reduction of research and development expenses. The Company records these reimbursements as a reduction of research and development expenses as the Company’s partner in the collaboration agreement has the financial risks and responsibility for conducting these research and development activities.
	Inventory
	Inventory, which consists of work-in-process and the finished product of LeukoScan, is stated at the lower of cost (which approximates first-in, first-out) or market, and includes materials, labor and manufacturing overhead.
	Inventory consisted of the following (in thousands):
			September 30,		June 30,
			2013		2013
	Work in process		$	914	$	914
	Finished goods			60		116
			$	974	$	1,030
	Income Taxes
	The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective tax bases. The Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change. We have recorded a full valuation allowance against our net deferred tax assets as of September 30, 2013.
	Income taxes were provided for profitable foreign jurisdictions at the estimated annual tax rate during the three-month periods ended September 30, 2013 and 2012. The Company’s U.S. operations reported a net loss for the three-month periods ended September 30, 2013 and 2012, resulting in a tax benefit that was fully offset by a valuation allowance.
	The Company has no liability for uncertain tax positions as of September 30, 2013.
	Net Loss Per Share Allocable to Common Stockholders
	Net loss per basic and diluted common share allocable to common stockholders is based on the net loss for the relevant period, divided by the weighted-average number of common shares outstanding during the period. For purposes of the diluted net loss per common share calculations, the exercise or conversion of all potential common shares is not included because their effect would have been anti-dilutive, due to the net loss recorded for the three-month periods ended September 30, 2013 and 2012. The common stock equivalents excluded from the diluted per share calculation are 7,708,560 and 7,596,825 shares at September 30, 2013 and 2012, respectively.
	Comprehensive Loss
	Comprehensive loss consists of net loss, unrealized loss on available for sale securities and foreign exchange translation adjustments and is presented in the condensed consolidated statements of comprehensive loss.
	Reclassification
	Certain prior period balances have been reclassified to conform to the current period presentation.
	Accounting Pronouncements
	In July 2013, the FASB issued Accounting Standard Update (“ASU”) 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carry-forward, a Similar Tax Loss, or a Tax Credit Carry-forward Exists.” This ASU will eliminate the diversity in practice in presentation of unrecognized tax benefits when a net operating loss carry-forward, a similar tax loss, or a tax credit carry-forward exists at the reporting date. This new guidance requires the netting of unrecognized tax benefits against a deferred tax asset for a loss or other carry-forward that would apply in settlement of the uncertain tax positions. Under the new guidance, unrecognized tax benefits will be netted against all available same-jurisdiction loss or other tax carry-forward that would be utilized, rather than only against carryforwards that are created by the unrecognized tax benefits. This guidance is effective prospectively, but allows optional retrospective adoption (for all periods presented), for reporting periods beginning after December 15, 2013. As this guidance relates to presentation only, the adoption of this guidance will not impact our financial position or results of operations.
	In February 2013, the FASB issued ASU 2013-02, “Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“AOCI”).” ASU requires entities to disclose additional information about reclassification adjustments, including changes in AOCI balances by component and significant items reclassified out of AOCI. The Company adopted this pronouncement in the first quarter of fiscal year 2014.

Marketable_Securities

Marketable Securities	3 Months Ended
	Sep. 30, 2013
Investments Debt And Equity Securities [Abstract]	'
Marketable Securities	'
	3. Marketable Securities
	During the three months ended September 30, 2013, the Company invested $20.1 million of cash and cash equivalents into debt securities and municipal bonds. Immunomedics utilized Accounting Standards Codification No. 320, Accounting for Investments – Debt and Equity Securities, to account for investments in marketable securities. Under this accounting standard, securities for which there are no positive intent and ability to hold to maturity, the securities are classified as available-for-sale and are carried at fair value. Unrealized holding gains and losses, which are deemed to be temporary, on securities classified as available-for-sale are carried as a separate component of accumulated other comprehensive income (loss). Immunomedics considers all of its current investments to be available-for-sale. Marketable securities at September 30, 2013 consist of the following (in thousands):
		Amortized		Gross		Gross			Estimated
		Cost		Unrealized		Unrealized			Fair
				Gain		Loss			Value
	September 30, 2013
	U.S. Treasury Bonds	$	9,048	$	1	$	(1	)	$	9,048
	Corporate Debt Securities		11,040		3		(8	)		11,035
		$	20,088	$	4	$	(9	)	$	20,083
	Maturities of debt securities classified as available-for-sale were as follows at September 30, 2013 (in thousands):
		Amortized		Estimated
		Cost		Fair
				Value
	Due within one year	$	10,063	$	10,062
	Due after one year through five years		10,025		10,021
		$	20,088	$	20,083

Stockholders_Equity

Stockholders Equity	3 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Stockholders Equity	'
	4. Stockholders Equity
	Accumulated Other Comprehensive Income
	The components of accumulated other comprehensive income were as follows:
			Currency		Net			Accumulated
			Translation		Unrealized			Other
			Adjustments		Losses on			Comprehensive
					Available-			Income
					for-Sale
					Securities
	Balance, July 1, 2013		$	161,830	$	—		$	161,830
	Other comprehensive income (loss) before reclassifications			72,367		(4,960	)		67,407
	Amounts reclassified from accumulated other comprehensive income(a)			—		—			—
	Net current-period other comprehensive income (loss)			72,367		(4,960	)		67,407
	Balance, September 30, 2013		$	234,197	$	(4,960	)	$	229,237
	All components of accumulated other comprehensive income are net of tax, except currency translation adjustments, which exclude income taxes related to indefinite investments in foreign subsidiaries.
	(a)	For the three months ended September 30, 2013, there were no amounts reclassified from accumulated other comprehensive income.

Stock_Incentive_Plan

Stock Incentive Plan	3 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock Incentive Plan	'
	5. Stock Incentive Plan
	A summary of the 2006 Stock Incentive Plan (the “Plan”), is provided in Note 6 to the audited financial statements contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2013. The Company believes that awards under the Plan better align the interests of its employees with those of its stockholders. Option awards are generally granted with an exercise price equal to the market price of the Company’s common stock at the date of grant; those option awards generally vest based on four years of continuous service and have seven year contractual terms. Option awards that are granted to non-employee Board members under the annual option grant program are granted with an exercise price equal to the market price of the Company’s common stock at the date of grant, are vested immediately and have seven year contractual terms. At September 30, 2013, there were 10,381,123 shares of common stock reserved for possible future issuance under the Plan, both currently outstanding (6,708,560 shares) and which were available to be issued for future grants (3,672,563 shares).
	The fair value of each option granted during the three-month periods ended September 30, 2013 and 2012 is estimated on the date of grant using the Black-Scholes option-pricing model with the weighted-average assumptions in the following table:
		Three-month period ended
		September 30,
		2013		2012
	Expected dividend yield	0%		0%
	Expected option term (years)	5.2		5.29
	Expected stock price volatility	67%		69%
	Risk-free interest rate	1.56%-1.74%		0.98%-1.11%
	The weighted average fair value at the date of grant for options granted during the three-month periods ended September 30, 2013 and 2012 were $3.07 and $2.02 per share, respectively. The Company uses historical data to estimate employee forfeitures for employees, executive officers and outside directors. The expected term of options granted represents the period of time that options granted are expected to be outstanding and the expected stock price volatility is based on the Company’s daily stock trading history. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.
	Information concerning options for the three-month period ended September 30, 2013 is summarized as follows:
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Life
	Outstanding, July 1, 2013		5,726,874		$	3.3
	Granted		800,131		$	5.32
	Exercised		(265,000	)	$	3.44
	Cancelled or forfeited		(468,786	)	$	5.29
	Outstanding, September 30, 2013		5,793,219		$	3.43		3.32	$	16,242,254
	Exercisable, September 30, 2013		4,487,484		$	3.21		2.52	$	13,421,695
	A summary of the Company’s non-vested restricted and performance stock units at July 1, 2013, and changes during the three-month period ended September 30, 2013 are presented below:
	Outstanding Non-Vested	Number of
	Restricted and Performance Stock Units	Awards
	Non-vested at July 1, 2013		488,575
	Restricted Units Granted		136,452
	Performance Units Granted		389,864
	Vested		(74,550	)
	Cancelled		(25,000	)
	Non-vested at September 30, 2013		915,341
	The Company has 2,221,076 non-vested options, restricted and performance stock units outstanding as of September 30, 2013. As of September 30, 2013, there was $3.0 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is being recognized over a weighted-average period of 3.0 years. The Company recorded $0.4 million and $0.5 million for total stock-based compensation expense for employees, executive officers and non-employee Board members for the three-month periods ended September 30, 2013 and 2012, respectively.
	Each non-employee Board member who continues to serve shall receive on the date of the annual stockholders meeting an annual grant of non-qualified stock options and restricted stock units, each equal in value to $45 thousand. The Company recorded $55 thousand and $16 thousand for stock-based compensation expense for these non-employee Board members restricted stock units for the three-month periods ended September 30, 2013 and 2012, respectively.
	On August 16, 2013, the Company awarded an additional 136,452 restricted stock units to certain executive officers of the Company at the market price on that date ($5.13 per share). These restricted stock units will vest over a four year period. As of September 30, 2013, there was $1.8 million of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Plan for these executive officers, excluding performance stock units. The $1.8 million cost is being recognized over a weighted-average period of 2.94 years. The Company recorded $0.1 million for stock-based compensation expense for each of the three-month periods ended September 30, 2013 and 2012.
	On August 16, 2013, the Company also awarded certain executive officers Performance Units which are subject to attainment of certain performance milestones as well as certain continued service requirements. All or a portion of the Performance Units shall vest based upon the level of achievement of the milestones set forth in each agreement, which is expected to be achieved within five years of the grant date. The Performance Units that vest based upon attainment of the Performance Milestone will be exercised based on a percentage basis on the attainment of anniversary dates. As of September 30, 2013, there are 389,864 Performance Units available if all performances are achieved within five years of grant date. The Company recorded $0.2 million for the stock-based compensation for the three-months ended September 30, 2013. There is $1.5 million of total unrecognized compensation cost related to these non-vested Performance Units granted as of September 30, 2013. That cost is being recognized over a weighted-average period of 1.3 years. The unrecognized compensation cost is subject to modification on a quarterly basis based on review of performance probability and requisite achievement periods.

Geographic_Segments

Geographic Segments	3 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Geographic Segments	'
	6. Geographic Segments
	Immunomedics manages its operations as one line of business of researching, developing, manufacturing and marketing biopharmaceutical products, particularly antibody-based products for cancer, autoimmune and other serious diseases, and it currently reports as a single industry segment. Immunomedics conducts its research and development activities primarily in the United States. Immunomedics markets and sells LeukoScan throughout Europe and in certain other countries outside the United States.
	The following table presents financial information based on the geographic location of the facilities of Immunomedics as of and for the three-months ended September 30, 2013 and 2012 ($ in thousands):
		As of and for the
		Three Months Ended
		September 30, 2013
		United			Europe			Total
		States
	Total assets	$	38,547		$	2,663		$	41,210
	Property and equipment, net		2,074			—			2,074
	Revenues		4,949			549			5,498
	Loss before taxes		(5,187	)		(35	)		(5,222	)
		As of and for the
		Three Months Ended
		September 30, 2012
		United			Europe			Total
		States
	Total assets	$	27,500		$	3,601		$	31,101
	Property and equipment, net		2,386			—			2,386
	Revenues		327			724			1,051
	(Loss) income before taxes		(7,185	)		38			(7,147	)

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	7. Related Party Transactions
	Certain of the Company’s affiliates, including members of its senior management and its Board of Directors, as well as their respective family members and other affiliates, have relationships and agreements among themselves as well as with the Company and its affiliates, that create the potential for both real, as well as perceived, conflicts of interest. These include Dr. David M. Goldenberg, the Chairman of the Board of Directors and Chief Medical Officer and Chief Scientific Officer, Ms. Cynthia L. Sullivan, the President and Chief Executive Officer, who is the wife of Dr. David M. Goldenberg, and certain companies with which the Company does business, including the Center for Molecular Medicine and Immunology (“CMMI”), and the Company’s majority-owned subsidiary IBC.
	Immunomedics, Inc. leases approximately 1,000 square feet of its Morris Plains, NJ facility to CMMI at a cost of approximately $30 thousand per year. The Company incurred $5 thousand and $8 thousand of legal expenses on behalf of CMMI for patent related matters for each of the three-month periods ended September 30, 2013 and 2012. The Company has first rights to license those patents, and may decide whether or not to support them. However, any inventions made independently of the Company by CMMI are the property of CMMI. On occasion, CMMI engages in research contracts on behalf of Immunomedics, Inc. There were zero and $25 thousand dollars in research related activities charged to the Company for the periods ending September 30, 2013 and 2012 respectively.
	For each of the three-month periods ended September 30, 2013 and 2012, Dr. Goldenberg received approximately $20 thousand in compensation for his services to IBC.

License_and_Collaboration_Agre

License and Collaboration Agreements	3 Months Ended
	Sep. 30, 2013
Text Block [Abstract]	'
License and Collaboration Agreements	'
	8. License and Collaboration Agreements
	Takeda Pharmaceutical/Nycomed GmbH
	On July 11, 2008, the Company entered into the Nycomed Agreement with Nycomed providing Nycomed a worldwide license to develop, manufacture and commercialize veltuzumab, the Company’s humanized anti-CD20 antibody, in the subcutaneous formulation, for the treatment of all non-cancer indications. The Company retained the rights to develop, manufacture and commercialize veltuzumab in the field of oncology. On September 30, 2011, Takeda Pharmaceutical Company Limited completed its acquisition of Nycomed and made Nycomed a wholly owned subsidiary of Takeda (“Takeda-Nycomed”) effective the same day.
	On October 3, 2013, the Company received notification from Takeda Pharmaceutical Company Limited/Nycomed GmbH of termination of the licensing agreement between Nycomed GmbH and Immunomedics for the worldwide rights to veltuzumab, the humanized anti-CD20 antibody, in a subcutaneous formulation for all non-cancer indications.
	The notification was received subsequent to the Company’s filing of arbitration proceedings in an effort to resolve the dispute the Company has with Nycomed concerning delays in the development of veltuzumab, which the Company argues is a material breach of the licensing agreement.
	As a result of the termination, all rights to veltuzumab revert to the Company and both parties have begun discussions regarding the transition of veltuzumab back to the Company. In addition, the Company will continue to pursue the arbitration procedure to address its claim for damages due to, among other things, delays in the development of veltuzumab.
	On October 11, 2013, Takeda filed its Statement of Defense with a counterclaim alleging wrongful termination of the licensing agreement. The Company will respond within 30 days. The Company expects an arbitrator to be selected on or before that date and that the arbitration will continue while the product transition takes place.
	Takeda-Nycomed was solely responsible for the development, manufacturing and commercialization of veltuzumab, for the subcutaneous formulation, for all non-cancer indications. The Company’s major obligations were to complete the research and development activities as specified in the Nycomed Agreement and to manufacture and supply veltuzumab to Takeda-Nycomed for the quantity of materials for the period of time specified in the Nycomed Agreement. The Company has completed all of its obligations under the agreement, namely its manufacturing and supply obligations and its responsibilities in the Phase I/II study in immune thrombocytopenic purpura (“ITP”).
	UCB, S.A.
	On May 9, 2006, the Company entered into an agreement with UCB, S.A. referred to herein as UCB, providing UCB an exclusive worldwide license to develop, manufacture, market and sell epratuzumab for the treatment of all non-cancer indications referred to herein as the UCB Agreement. Under the terms of the UCB Agreement, the Company received from UCB a non-refundable cash payment totaling $38.0 million.
	On December 27, 2011, the Company entered into the Amendment Agreement with UCB referred to herein as the Amendment Agreement. The Amendment Agreement provided UCB the right to sublicense epratuzumab, subject to obtaining our prior consent, to a third party for the United States and certain other territories. As of September 30, 2013, UCB has not executed a sublicense agreement with a third-party.
	The Company also issued to UCB on December 27, 2011 a 5-year warrant to purchase one million shares of the Company’s common stock, par value $0.01 per share, at an exercise price of $8.00 per share. In exchange for the right to sublicense its rights in epratuzumab to a third party and the warrant issuance, the Company received a non-refundable cash payment of $30.0 million in January 2012. Further, under the terms of the Amendment Agreement, UCB surrendered its buy-in right with respect to epratuzumab in the field of oncology, which had been granted under the UCB Agreement.
	Collectively, pursuant to the UCB Agreement and the Amendment Agreement the Company is entitled to receive (i) up to $145.0 million in cash payments and $20.0 million in equity investments in regulatory milestone payments and (ii) up to $260.0 million related to the achievement of specified product sales milestones. The Company is also entitled to product royalties ranging from a mid-teen to mid-twenty percentage of aggregate annual net sales under the UCB Agreement during the product royalty term. No development milestone, commercialization milestone or royalty payments were achieved through September 30, 2013. There can be no assurance that the development or commercialization milestones or royalty payment thresholds under the UCB Agreement and Amendment Agreement will be met and therefore there can be no assurance that the Company will receive such future payments.
	The Agreement commenced on May 9, 2006 and shall terminate in accordance with the terms thereof or by mutual written consent, unless UCB decides to cease all development and commercialization of epratuzumab pursuant to the Agreement. Either the Company or UCB has the right to terminate the Agreement by notice in writing to the other party upon or after any material breach of the Agreement by the other party, if the other party has not cured the breach within 60 days after written notice to cure has been given, with certain exceptions. Upon termination of the Agreement, among other things, all rights and licenses granted by the Company to UCB shall terminate, all rights of UCB under the Immunomedics Patent Rights (as defined in the Agreement) and Immunomedics Know-How (as defined in the Agreement) shall revert to the Company, and UCB shall cease all use of the Immunomedics Patent Rights and Immunomedics Know-How. Further, all regulatory filings and Approvals (as defined in the Agreement) and any other documents relating to or necessary to further develop and commercialize the Licensed Compound (as defined in the Agreement) and Licensed Products (as defined in the Agreement), including, without limitation, all sublicenses granted by UCB, and all of UCB’s right, title and interest therein and thereto, shall be assigned to the Company at the Company’s option. No additional amounts shall be payable on events occurring after the effective date of termination.
	Algeta ASA
	In January 2013, the Company entered into a collaboration agreement with Algeta ASA for the development of epratuzumab to be conjugated with Algeta’s proprietary thorium-227 alpha-pharmaceutical payload. On August 2, 2013, an amendment to the collaboration agreement was entered into between the two companies modifying certain delivery and supply parameters. Under the terms of this agreement, as amended, the Company is required to manufacture and supply clinical-grade epratuzumab antibody to Algeta, which has rights to evaluate the potential of a Targeted Thorium Conjugate (TTC), linking thorium-227 to epratuzumab, for the treatment of cancer. Algeta will fund all preclinical and clinical development costs up to the end of Phase I testing. Upon successful completion of Phase I testing, the parties shall negotiate terms for a license agreement at Algeta’s request. The Company and Algeta agreed to certain parameters in the collaboration agreement. Under the terms of the collaboration agreement, as amended, Immunomedics received an upfront cash payment and other payments which have been recognized upon the Company fulfilling its obligations under the collaboration agreement. For the three-month period ended September 30, 2013, the Company recognized $4.6 million of revenue under this arrangement, which has been included in license fee and other revenues, while the related costs of $1.2 million is included in cost of license fee and other revenue. As of September 30, 2013, the Company recognized all of the initial cash payments as revenue as the aspects of delivery for the clinical supply material have been satisfied.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	9. Commitments and Contingencies
	Employment Contracts
	Effective July 1, 2011, the Company entered into the Third Amended and Restated Employment Agreement with Dr. Goldenberg for his service to the Company as the Chief Scientific Officer and Chief Medical Officer (the “Goldenberg Agreement”), which terminates July 1, 2016. This agreement covers aspects of his compensation as well as duties and responsibilities at Immunomedics. Under this agreement Dr. Goldenberg’s annual base salary is at a minimum of $0.5 million, which shall be reviewed annually for appropriate increases by the Board of Directors or the Compensation Committee (increased 3.5% for the 2014 fiscal year). Dr. Goldenberg will also be eligible to participate in any Company incentive compensation plan in place for its senior level executives and is eligible to receive an annual discretionary bonus based upon certain performance standards to be determined by the Compensation Committee. Dr. Goldenberg’s annual bonus target is 50% of his annual base salary, subject to achievement of performance goals, with a potential payout from 0 to 150% of the target amount.
	Under the Goldenberg Agreement, Dr. Goldenberg is eligible to receive certain additional incentive compensation during the agreement term, including being eligible to receive royalty payments from royalties received by the Company. For each fiscal year, the Company shall pay Dr. Goldenberg a sum equal to a percentage of the annual royalties the Company receives on each of the products for which Dr. Goldenberg is an inventor, and all products using, related to or derived from products for which Dr. Goldenberg is an inventor. The percentage of royalties that the Company will pay to Dr. Goldenberg on each patented product will be determined based on the percentage of royalties that the Company must pay to external third parties.
	Under the terms of the Goldenberg Agreement, the Company makes a minimum quarterly payment of $37.5 thousand to Dr. Goldenberg during each of the fiscal years during the Goldenberg Agreement, as an advance against the amounts due as additional incentive compensation, royalty payments and dispositions of undeveloped assets. For the three-month periods ended September 30, 2013 and 2012, no additional incentive compensation payments were made to Dr. Goldenberg other than the $37.5 thousand minimum quarterly payments.
	On July 1, 2011, the Company and Cynthia L. Sullivan entered into the Fourth Amended and Restated Employment Agreement pertaining to Ms. Sullivan’s service as the Company’s President and Chief Executive Officer. The Amended Sullivan Agreement shall terminate on July 1, 2014. Ms. Sullivan’s annual base salary under the agreement is $0.6 million, which shall be reviewed annually for appropriate increases by the Board of Directors or the Compensation Committee (increased by 3.5% for the 2014 fiscal year). Ms. Sullivan is also eligible to participate in the Company’s incentive compensation plan in place for its senior level executives. Ms. Sullivan’s annual bonus target is 50% of her base salary, subject to achievement of performance goals, with a potential payout from 0 to 150% of the target amount. Ms. Sullivan will also be eligible to receive equity compensation awards under the Company’s 2006 Stock Incentive Plan, or any such successor equity compensation plan as may be in place from time to time.
	Legal Matters
	In the ordinary course of business, the Company may be subject to legal proceedings and claims. At this time, the Company is not a party to any legal proceedings, claims or assessments that, in management’s opinion, would have a material adverse effect on the Company’s business, financial condition or results of operations.

Subsequent_Event

Subsequent Event	3 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Event	'
	10. Subsequent Event
	On October 3, 2013, the Company received notification from Takeda Pharmaceutical Company/Nycomed GmbH of the termination of the licensing agreement between Nycomed GmbH and Immunomedics for the worldwide rights to veltuzumab, the humanized anti-CD20 antibody, in a subcutaneous formulation for all non-cancer indications.
	The notification was received subsequent to the Company’s filing of arbitration proceedings in an effort to resolve the dispute the Company has with Nycomed concerning delays in the development of veltuzumab, which the Company argues is a material breach of the licensing agreement.
	As a result of the termination, all rights to veltuzumab revert to the Company and both parties have begun discussions regarding the transition of veltuzumab back to the Company. In addition, the Company will continue to pursue the arbitration procedure to address its claim for damages due to, among other things, delays in the development of veltuzumab.
	On October 11, 2013, Takeda filed its Statement of Defense with a counterclaim alleging wrongful termination of the licensing agreement. The Company will respond within 30 days. The Company expects an arbitrator to be selected on or before that date and that the arbitration will continue while the product transition takes place.

Correction_of_Immaterial_Error

Correction of Immaterial Error	3 Months Ended
	Sep. 30, 2013
Accounting Changes And Error Corrections [Abstract]	'
Correction of Immaterial Error	'
	11. Correction of Immaterial Error
	Subsequent to the issuance of the Company’s consolidated financial statements for the fiscal year ended June 30, 2013, the Company identified and corrected an error in its accounting for clinical trial expense and accrued liabilities. As a result, the Company recorded an out of period adjustment of $1.2 million to correct the overstatement of the accrued liability for clinical trials as of June 30, 2013 as a reduction of accounts payable and accrued expenses and research and development expense to the interim condensed financial statements as of September 30, 2013 and for the three-month period then ended. Additional information has been identified and the total amount of the overstatement of the accrued liability for clinical trials as of June 30, 2013 was determined to be $3.2 million. Due to this error, the Company’s operating expenses and accrued liabilities were overstated during each of the fiscal years 2008-2013. The tax consequence of this correction is limited to the reduction of deferred tax assets related to net operating losses of $1.3 million with an offsetting reduction in the related valuation allowance.
	The Company assessed the materiality of this error for each quarterly and annual period in accordance with Staff Accounting Bulletin No. 99, Materiality, and determined that the error was immaterial to each of the previously reported periods.
	The effect of recording this immaterial error correction affects the presentation of the comparative condensed consolidated statements of comprehensive loss for the three months ended September 31, 2013 and 2012, and the condensed consolidated balance sheets as of September 30, 2013 and June 30, 2013 for certain line items associated with the Statements of Comprehensive Loss and Balance Sheet as set forth below (in thousands):
		Three months ended						Three months ended
		September 30, 2013						September 30, 2012
		(As			(As			(As			(As
		Reported)			Revised)			Reported)			Revised)
	Statements of Comprehensive Loss
	Research and development	$	6,653		$	7,514		$	7,035		$	6,794
	Net loss		(4,365	)		(5,226	)		(7,408	)		(7,167	)
	Net loss attributable to Immunomedics, Inc. stockholders		(4,339	)		(5,200	)		(7,382	)		(7,141	)
		As of September 30, 2013						As of June 30, 2013
		(As			(As			(As			(As
		Reported)			Revised)			Reported)			Revised)
	Balance Sheets
	Accounts payable and accrued expenses	$	6,066		$	3,713		$	7,165		$	3,951
	Accumulated deficit		(233,593	)		(231,240	)		(229,254	)		(226,040	)
	Total Immunomedics, Inc. stockholders’ equity		33,864			36,216			36,966			40,180
	These corrections did not impact cash flows from operating activities for the three-month periods ended September 30, 2013 or 2012.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Principles of Consolidation and Presentation	'
	Principles of Consolidation and Presentation
	The condensed consolidated financial statements include the accounts of Immunomedics and its subsidiaries. Noncontrolling interests in consolidated subsidiaries in the condensed consolidated balance sheets represent minority stockholders’ proportionate share of the equity (deficit) in such subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Revenue Recognition	'
	Revenue Recognition
	The Company has accounted for revenue arrangements that include multiple deliverables as a separate unit of accounting if: a) the delivered item has value to the customer on a standalone basis, and b) the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered items is considered probable and substantially in the control of the vendor, in accordance with the accounting standard for multiple-element arrangements. If these criteria are not met, the revenue elements must be considered a single unit of accounting for purposes of revenue recognition. The Company allocates revenue consideration, excluding contingent consideration, based on the relative selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Relative selling prices are determined using vendor specific objective evidence, if it exists; otherwise third-party evidence or the Company’s best estimate of selling price is used for each deliverable.
	Payments received under contracts to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Payments received in advance that are related to future performance are deferred and recognized as revenue when the research projects are performed or the product is delivered. Upfront nonrefundable fees associated with license and development agreements where the Company has continuing obligations in the agreement are recorded as deferred revenue and recognized over the estimated service period. If the estimated service period is subsequently modified, the period over which the upfront fee is recognized is modified accordingly on a prospective basis.
	In order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards (“FASB”) guidance on the milestone method of revenue recognition at the inception of a collaboration agreement. The criteria requires that (i) the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company’s activities to achieve the milestone, (ii) the milestone be related to past performance, and (iii) the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met, then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved. Royalties are recognized as earned in accordance with the terms of various research and collaboration agreements.
	Revenue from the sale of diagnostic products is recorded when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. Allowances, if any, are established for uncollectible amounts, estimated product returns and discounts. Since allowances are recorded based on management’s estimates, actual amounts may be different in the future.
Research and Development Costs	'
	Research and Development Costs
	Research and development costs are expensed as incurred. Costs incurred for clinical trials for patients and investigators are expensed as services are performed in accordance with the agreements in place with the institutions.
Manufacturing Costs	'
	Manufacturing Costs
	Manufacturing costs incurred in relation to the development of materials produced in order to fulfill contractual obligations are capitalized and are recorded in other current assets until the product is delivered in accordance with the terms of the agreement. These manufacturing costs are classified as cost of license fee and other revenues when the research contractual obligations have been completed.
Financial Instruments	'
	Financial Instruments
	The carrying amounts of cash and cash equivalents, other current assets and current liabilities approximate fair value due to the short-term maturity of these instruments. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Investments in marketable securities are available-for-sale to fund operations. The portfolio at September 30, 2013 primarily consists of corporate debt securities and municipal bonds.
Estimated Fair Value of Financial Instruments	'
	Estimated Fair Value of Financial Instruments
	The Company has categorized its financial assets, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. The Company does not have any financial liabilities that are required to be measured at fair value on a recurring basis. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
	Financial assets recorded on the condensed consolidated balance sheets as of September 30, 2013 and June 30, 2013 are categorized based on the inputs to the valuation techniques as follows (in thousands):
		•		Level 1 – Financial assets whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the company has the ability to access at the measurement date (examples include active exchange-traded equity securities and most U.S. Government and agency securities).
		•		Level 2 – Financial assets whose value are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.
		•		Level 3 – Financial assets whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset.
			($ in thousands)
	September 30, 2013		Level 1		Level 2		Level 3		Total
	Money Market Funds		$	11,144	$	—	$	—	$	11,144
	Marketable Securities			20,083		—		—		20,083
	Total		$	31,227	$	—	$	—	$	31,227
	June 30, 2013		Level 1		Level 2		Level 3		Total
	Money Market Funds		$	38,327	$	—	$	—	$	38,327
	Total		$	38,327	$	—	$	—	$	38,327
	The money market funds noted above are included in cash and cash equivalents.
Reimbursement of Research & Development Costs	'
	Reimbursement of Research & Development Costs
	Research and development costs that are reimbursable under collaboration agreements are included as a reduction of research and development expenses. The Company records these reimbursements as a reduction of research and development expenses as the Company’s partner in the collaboration agreement has the financial risks and responsibility for conducting these research and development activities.
Inventory	'
	Inventory
	Inventory, which consists of work-in-process and the finished product of LeukoScan, is stated at the lower of cost (which approximates first-in, first-out) or market, and includes materials, labor and manufacturing overhead.
	Inventory consisted of the following (in thousands):
			September 30,		June 30,
			2013		2013
	Work in process		$	914	$	914
	Finished goods			60		116
			$	974	$	1,030
Income Taxes	'
	Income Taxes
	The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective tax bases. The Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change. We have recorded a full valuation allowance against our net deferred tax assets as of September 30, 2013.
	Income taxes were provided for profitable foreign jurisdictions at the estimated annual tax rate during the three-month periods ended September 30, 2013 and 2012. The Company’s U.S. operations reported a net loss for the three-month periods ended September 30, 2013 and 2012, resulting in a tax benefit that was fully offset by a valuation allowance.
	The Company has no liability for uncertain tax positions as of September 30, 2013.
Net Loss Per Share Allocable to Common Stockholders	'
	Net Loss Per Share Allocable to Common Stockholders
	Net loss per basic and diluted common share allocable to common stockholders is based on the net loss for the relevant period, divided by the weighted-average number of common shares outstanding during the period. For purposes of the diluted net loss per common share calculations, the exercise or conversion of all potential common shares is not included because their effect would have been anti-dilutive, due to the net loss recorded for the three-month periods ended September 30, 2013 and 2012. The common stock equivalents excluded from the diluted per share calculation are 7,708,560 and 7,596,825 shares at September 30, 2013 and 2012, respectively.
Comprehensive Loss	'
	Comprehensive Loss
	Comprehensive loss consists of net loss, unrealized loss on available for sale securities and foreign exchange translation adjustments and is presented in the condensed consolidated statements of comprehensive loss.
Reclassification	'
	Reclassification
	Certain prior period balances have been reclassified to conform to the current period presentation.
Accounting Pronouncements	'
	Accounting Pronouncements
	In July 2013, the FASB issued Accounting Standard Update (“ASU”) 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carry-forward, a Similar Tax Loss, or a Tax Credit Carry-forward Exists.” This ASU will eliminate the diversity in practice in presentation of unrecognized tax benefits when a net operating loss carry-forward, a similar tax loss, or a tax credit carry-forward exists at the reporting date. This new guidance requires the netting of unrecognized tax benefits against a deferred tax asset for a loss or other carry-forward that would apply in settlement of the uncertain tax positions. Under the new guidance, unrecognized tax benefits will be netted against all available same-jurisdiction loss or other tax carry-forward that would be utilized, rather than only against carryforwards that are created by the unrecognized tax benefits. This guidance is effective prospectively, but allows optional retrospective adoption (for all periods presented), for reporting periods beginning after December 15, 2013. As this guidance relates to presentation only, the adoption of this guidance will not impact our financial position or results of operations.
	In February 2013, the FASB issued ASU 2013-02, “Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“AOCI”).” ASU requires entities to disclose additional information about reclassification adjustments, including changes in AOCI balances by component and significant items reclassified out of AOCI. The Company adopted this pronouncement in the first quarter of fiscal year 2014.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Financial Assets Recorded on Condensed Consolidated Balance Sheets	'
	Financial assets recorded on the condensed consolidated balance sheets as of September 30, 2013 and June 30, 2013 are categorized based on the inputs to the valuation techniques as follows (in thousands):
		•		Level 1 – Financial assets whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the company has the ability to access at the measurement date (examples include active exchange-traded equity securities and most U.S. Government and agency securities).
		•		Level 2 – Financial assets whose value are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.
		•		Level 3 – Financial assets whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset.
			($ in thousands)
	September 30, 2013		Level 1		Level 2		Level 3		Total
	Money Market Funds		$	11,144	$	—	$	—	$	11,144
	Marketable Securities			20,083		—		—		20,083
	Total		$	31,227	$	—	$	—	$	31,227
	June 30, 2013		Level 1		Level 2		Level 3		Total
	Money Market Funds		$	38,327	$	—	$	—	$	38,327
	Total		$	38,327	$	—	$	—	$	38,327
Schedule of Inventory	'
	Inventory consisted of the following (in thousands):
			September 30,		June 30,
			2013		2013
	Work in process		$	914	$	914
	Finished goods			60		116
			$	974	$	1,030

Marketable_Securities_Tables

Marketable Securities (Tables)	3 Months Ended
	Sep. 30, 2013
Investments Debt And Equity Securities [Abstract]	'
Components of Marketable Securities	'
	Marketable securities at September 30, 2013 consist of the following (in thousands):
		Amortized		Gross		Gross			Estimated
		Cost		Unrealized		Unrealized			Fair
				Gain		Loss			Value
	September 30, 2013
	U.S. Treasury Bonds	$	9,048	$	1	$	(1	)	$	9,048
	Corporate Debt Securities		11,040		3		(8	)		11,035
		$	20,088	$	4	$	(9	)	$	20,083
Maturities of Debt Securities Classified as Available-for-Sale	'
	Maturities of debt securities classified as available-for-sale were as follows at September 30, 2013 (in thousands):
		Amortized		Estimated
		Cost		Fair
				Value
	Due within one year	$	10,063	$	10,062
	Due after one year through five years		10,025		10,021
		$	20,088	$	20,083

Stockholders_Equity_Tables

Stockholders Equity (Tables)	3 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Components of Accumulated Other Comprehensive Income	'
	The components of accumulated other comprehensive income were as follows:
			Currency		Net			Accumulated
			Translation		Unrealized			Other
			Adjustments		Losses on			Comprehensive
					Available-			Income
					for-Sale
					Securities
	Balance, July 1, 2013		$	161,830	$	—		$	161,830
	Other comprehensive income (loss) before reclassifications			72,367		(4,960	)		67,407
	Amounts reclassified from accumulated other comprehensive income(a)			—		—			—
	Net current-period other comprehensive income (loss)			72,367		(4,960	)		67,407
	Balance, September 30, 2013		$	234,197	$	(4,960	)	$	229,237
	All components of accumulated other comprehensive income are net of tax, except currency translation adjustments, which exclude income taxes related to indefinite investments in foreign subsidiaries.
	(a)	For the three months ended September 30, 2013, there were no amounts reclassified from accumulated other comprehensive income.

Stock_Incentive_Plan_Tables

Stock Incentive Plan (Tables)	3 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Options Weighted-Average Assumptions	'
	The fair value of each option granted during the three-month periods ended September 30, 2013 and 2012 is estimated on the date of grant using the Black-Scholes option-pricing model with the weighted-average assumptions in the following table:
		Three-month period ended
		September 30,
		2013		2012
	Expected dividend yield	0%		0%
	Expected option term (years)	5.2		5.29
	Expected stock price volatility	67%		69%
	Risk-free interest rate	1.56%-1.74%		0.98%-1.11%
Summary of Options	'
	Information concerning options for the three-month period ended September 30, 2013 is summarized as follows:
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Life
	Outstanding, July 1, 2013		5,726,874		$	3.3
	Granted		800,131		$	5.32
	Exercised		(265,000	)	$	3.44
	Cancelled or forfeited		(468,786	)	$	5.29
	Outstanding, September 30, 2013		5,793,219		$	3.43		3.32	$	16,242,254
	Exercisable, September 30, 2013		4,487,484		$	3.21		2.52	$	13,421,695
Non-Vested Restricted and Performance Stock Units	'
	A summary of the Company’s non-vested restricted and performance stock units at July 1, 2013, and changes during the three-month period ended September 30, 2013 are presented below:
	Outstanding Non-Vested	Number of
	Restricted and Performance Stock Units	Awards
	Non-vested at July 1, 2013		488,575
	Restricted Units Granted		136,452
	Performance Units Granted		389,864
	Vested		(74,550	)
	Cancelled		(25,000	)
	Non-vested at September 30, 2013		915,341

Geographic_Segments_Tables

Geographic Segments (Tables)	3 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Financial Information Based on Geographic Location of Facilities	'
	The following table presents financial information based on the geographic location of the facilities of Immunomedics as of and for the three-months ended September 30, 2013 and 2012 ($ in thousands):
		As of and for the
		Three Months Ended
		September 30, 2013
		United			Europe			Total
		States
	Total assets	$	38,547		$	2,663		$	41,210
	Property and equipment, net		2,074			—			2,074
	Revenues		4,949			549			5,498
	Loss before taxes		(5,187	)		(35	)		(5,222	)
		As of and for the
		Three Months Ended
		September 30, 2012
		United			Europe			Total
		States
	Total assets	$	27,500		$	3,601		$	31,101
	Property and equipment, net		2,386			—			2,386
	Revenues		327			724			1,051
	(Loss) income before taxes		(7,185	)		38			(7,147	)

Correction_of_Immaterial_Error1

Correction of Immaterial Error (Tables)	3 Months Ended
	Sep. 30, 2013
Accounting Changes And Error Corrections [Abstract]	'
Effect of Recording this Correction in Consolidated Statements of Comprehensive Loss	'
	The effect of recording this immaterial error correction affects the presentation of the comparative condensed consolidated statements of comprehensive loss for the three months ended September 31, 2013 and 2012, and the condensed consolidated balance sheets as of September 30, 2013 and June 30, 2013 for certain line items associated with the Statements of Comprehensive Loss and Balance Sheet as set forth below (in thousands):
		Three months ended						Three months ended
		September 30, 2013						September 30, 2012
		(As			(As			(As			(As
		Reported)			Revised)			Reported)			Revised)
	Statements of Comprehensive Loss
	Research and development	$	6,653		$	7,514		$	7,035		$	6,794
	Net loss		(4,365	)		(5,226	)		(7,408	)		(7,167	)
	Net loss attributable to Immunomedics, Inc. stockholders		(4,339	)		(5,200	)		(7,382	)		(7,141	)
Effect of Recording this Correction in Consolidated Balance Sheet	'
		As of September 30, 2013						As of June 30, 2013
		(As			(As			(As			(As
		Reported)			Revised)			Reported)			Revised)
	Balance Sheets
	Accounts payable and accrued expenses	$	6,066		$	3,713		$	7,165		$	3,951
	Accumulated deficit		(233,593	)		(231,240	)		(229,254	)		(226,040	)
	Total Immunomedics, Inc. stockholders’ equity		33,864			36,216			36,966			40,180

Business_Overview_and_Basis_of1

Business Overview and Basis of Presentation - Additional Information (Detail) (USD $)	3 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2012	Jun. 30, 2012
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Number of subsidiaries	2	'	'	'
Cash, cash equivalents and marketable securities	$34,700,000	'	'	'
Cash and cash equivalents	14,643,050	41,326,000	25,520,318	32,838,096
Minimum [Member]	'	'	'	'
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Cash and cash equivalents	24,000,000	'	'	'
Maximum [Member]	'	'	'	'
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Cash and cash equivalents	$26,000,000	'	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]	'	'
Highly liquid investments, original maturity period	'3 months	'
Liability for uncertain tax positions	$0	'
Common stock equivalents excluded from the diluted per share calculation	7,708,560	7,596,825

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Financial Assets Recorded on Condensed Consolidated Balance Sheets (Detail) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	$31,227	$38,327
Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	11,144	38,327
Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	20,083	'
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	31,227	38,327
Level 1 [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	11,144	38,327
Level 1 [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	20,083	'
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Level 2 [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Level 2 [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Level 3 [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Level 3 [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Schedule of Inventory (Detail) (USD $)	Sep. 30, 2013	Jun. 30, 2013
Inventory Disclosure [Abstract]	'	'
Work in process	$914,000	$914,000
Finished goods	60,000	116,000
Total	$973,642	$1,030,480

Marketable_Securities_Addition

Marketable Securities - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Investments Debt And Equity Securities [Abstract]	'
Cash and cash equivalents investments into debt securities and municipal bonds	$20.10

Marketable_Securities_Componen

Marketable Securities - Components of Marketable Securities (Detail) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'
Amortized Cost	$20,088
Gross Unrealized Gain	4
Gross Unrealized Loss	-9
Estimated Fair Value	20,083
U.S. Treasury Bonds [Member]	'
Schedule of Available-for-sale Securities [Line Items]	'
Amortized Cost	9,048
Gross Unrealized Gain	1
Gross Unrealized Loss	-1
Estimated Fair Value	9,048
Corporate Debt Securities [Member]	'
Schedule of Available-for-sale Securities [Line Items]	'
Amortized Cost	11,040
Gross Unrealized Gain	3
Gross Unrealized Loss	-8
Estimated Fair Value	$11,035

Marketable_Securities_Maturiti

Marketable Securities - Maturities of Debt Securities Classified As Available-for-Sale (Detail) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Amortized Cost And Fair Value Debt Securities [Abstract]	'
Amortized cost, Due within one year	$10,063
Amortized cost , Due after one year through five years	10,025
Amortized cost	20,088
Estimated Fair Value, Due within one year	10,062
Estimated Fair Value, Due after one year through five years	10,021
Estimated Fair Value	$20,083

Stockholders_Equity_Components

Stockholders Equity - Components of Accumulated Other Comprehensive Income (Detail) (USD $)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'
Balance, July 1, 2013	$161,830	'
Other comprehensive income	67,407	60,146
Balance, September 30, 2013	229,237	'
Accumulated Other Comprehensive Income [Member]	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'
Balance, July 1, 2013	161,830	'
Other comprehensive income (loss) before reclassifications	67,407	'
Amounts reclassified from accumulated other comprehensive income	0	'
Other comprehensive income	67,407	'
Balance, September 30, 2013	229,237	'
Currency Translation Adjustments [Member]	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'
Balance, July 1, 2013	161,830	'
Other comprehensive income (loss) before reclassifications	72,367	'
Other comprehensive income	72,367	'
Balance, September 30, 2013	234,197	'
Net Unrealized Gains (Losses) on Available-for-Sale Securities [Member]	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'
Other comprehensive income (loss) before reclassifications	-4,960	'
Other comprehensive income	-4,960	'
Balance, September 30, 2013	($4,960)	'

Stockholders_Equity_Components1

Stockholders Equity - Components of Accumulated Other Comprehensive Income (Parenthetical) (Detail) (Accumulated Other Comprehensive Income [Member], USD $)	3 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income [Member]	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Reclassified from accumulated other comprehensive income	$0

Stock_Incentive_Plan_Additiona

Stock Incentive Plan - Additional Information (Detail) (USD $)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Aug. 16, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Performance Units vesting period	'4 years	'	'
Contractual terms of stock option	'7 years	'	'
Common stock reserved for possible future issuance upon exercise of stock options	10,381,123	'	'
Stock options available for future grants	6,708,560	'	'
Stock options to be issued for future grants	3,672,563	'	'
Weighted average fair value at the date of grant for options granted	$3.07	$2.02	'
Non-vested options outstanding	2,221,076	'	'
Unrecognized compensation costs related to non-vested share-based compensation	$3,000,000	'	'
Weighted-average period recognized	'3 years	'	'
Restricted Stock [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Performance Units vesting period	'4 years	'	'
Value of shares to be granted for non-employee Board members	45,000	'	'
Stock-based compensation expense	55,000	16,000	'
Performance Units granted	136,452	'	'
Stock Option [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Value of shares to be granted for non-employee Board members	45,000	'	'
Performance Units [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Unrecognized compensation costs related to non-vested share-based compensation	1,500,000	'	'
Weighted-average period recognized	'1 year 3 months 18 days	'	'
Performance Units granted	389,864	'	'
Stock-based compensation	200,000	'	'
Performance Units [Member] | Maximum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Performance Units vesting period	'5 years	'	'
Employees, Executive Officers and Non-Employee Board Members [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation expense related stock options	400,000	500,000	'
Board Members [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Contractual terms of stock option	'7 years	'	'
Executive Officers [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Unrecognized compensation costs related to non-vested share-based compensation	1,800,000	'	'
Stock-based compensation expense related stock options	$100,000	$100,000	'
Weighted-average period recognized	'2 years 11 months 9 days	'	'
Restricted stock units	'	'	136,452
Restricted stock units, market price	'	'	$5.13

Stock_Incentive_Plan_Schedule_

Stock Incentive Plan - Schedule of Options Weighted-Average Assumptions (Detail)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Expected dividend yield	0.00%	0.00%
Expected option term (years)	'5 years 2 months 12 days	'5 years 3 months 15 days
Expected stock price volatility	67.00%	69.00%
Risk-free interest rate, minimum	1.56%	0.98%
Risk-free interest rate, maximum	1.74%	1.11%

Stock_Incentive_Plan_Summary_o

Stock Incentive Plan - Summary of Options (Detail) (USD $)	3 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Number of Shares, Options outstanding, beginning of year	5,726,874
Number of Shares, Options granted	800,131
Number of Shares, Options exercised	-265,000
Number of Shares, Options cancelled or forfeited	-468,786
Number of Shares, Options outstanding, end of year	5,793,219
Number of Shares, Options exercisable, end of year	4,487,484
Weighted Average Exercise Price, Options outstanding, beginning of year	$3.30
Weighted Average Exercise Price, Options granted	$5.32
Weighted Average Exercise Price, Options exercised	$3.44
Weighted Average Exercise Price, Options cancelled or forfeited	$5.29
Weighted Average Exercise Price, Options outstanding, end of year	$3.43
Weighted Average Exercise Price, Options exercisable, end of year	$3.21
Weighted Average Remaining Contractual Life of outstanding stock options	'3 years 3 months 26 days
Weighted Average Remaining Contractual Life of exercisable stock options	'2 years 6 months 7 days
Aggregate Intrinsic Value of outstanding stock options	$16,242,254
Aggregate Intrinsic Value of exercisable stock options	$13,421,695

Stock_Incentive_Plan_NonVested

Stock Incentive Plan - Non-Vested Restricted and Performance Stock Units (Detail)	3 Months Ended
	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Non-vested at July 1, 2013	488,575
Vested	-74,550
Cancelled	-25,000
Non-vested at September 30, 2013	915,341
Restricted Stock [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Granted	136,452
Performance Units [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Granted	389,864

Geographic_Segments_Financial_

Geographic Segments - Financial Information Based on Geographic Location of Facilities (Detail) (USD $)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Jun. 30, 2013
Segment Reporting Information [Line Items]	'	'	'
Total assets	$41,210,126	$31,101,000	$47,927,353
Property and equipment, net	2,074,487	2,386,000	2,086,911
Revenues	5,497,821	1,051,418	'
(Loss) income before taxes	-5,221,682	-7,147,148	'
United States [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Total assets	38,547,000	27,500,000	'
Property and equipment, net	2,074,000	2,386,000	'
Revenues	4,949,000	327,000	'
(Loss) income before taxes	-5,187,000	-7,185,000	'
Europe [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Total assets	2,663,000	3,601,000	'
Revenues	549,000	724,000	'
(Loss) income before taxes	($35,000)	$38,000	'

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Related Party Transaction [Line Items]	'	'
Compensation received for services	$20	$20
Center for Molecular Medicine and Immunology [Member]	'	'
Related Party Transaction [Line Items]	'	'
Area of subleased property	1,000	'
Subleases cost	30	'
Legal expenses incurred by the company	5	8
Reimbursed expenses incurred on behalf of company	$0	$25

License_and_Collaboration_Agre1

License and Collaboration Agreements - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended				0 Months Ended	3 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Dec. 27, 2011	Jan. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	9-May-06	Sep. 30, 2013
				Regulatory Milestones [Member]	Regulatory Milestones [Member]	Regulatory Milestones [Member]	UCB Agreement [Member]	Algeta Agreement [Member]
				Cash Payments [Member]	Equity Investments [Member]	Specified Product Sales [Member]
Goodwill [Line Items]	'	'	'	'	'	'	'	'
Non-refundable cash payment received	'	$30,000,000	'	'	'	'	$38,000,000	'
Duration of warrant issued	'5 years	'	'	'	'	'	'	'
Number of shares under five year warrant	1	'	'	'	'	'	'	'
Shares to be purchased under warrant, par value	$0.01	'	'	'	'	'	'	'
Shares to be purchased under warrant, exercise price	$8	'	'	'	'	'	'	'
Amendment agreement description	'	'	'(i) up to $145.0 million in cash payments and $20.0 million in equity investments in regulatory milestone payments and (ii) up to $260.0 million related to the achievement of specified product sales milestones.	'	'	'	'	'
UCB Agreement and the Amendment Agreement, receivable	'	'	'	145,000,000	20,000,000	260,000,000	'	'
Product royalties term, description	'	'	'The Company is also entitled to product royalties ranging from a mid-teen to mid-twenty percentage of aggregate annual net sales under the UCB Agreement during the product royalty term.	'	'	'	'	'
Additional amounts payable after effective date of termination	'	'	0	'	'	'	'	'
License fee revenue	'	'	'	'	'	'	'	4,600,000
Cost of license fee and other revenues	'	'	$1,189,170	'	'	'	'	$1,200,000

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	3 Months Ended
	Sep. 30, 2013
Dr. David M. Goldenberg [Member]	'
Guarantor Obligations [Line Items]	'
Percentage of increase in annual base salary for next fiscal year	3.50%
Minimum additional incentive compensation, royalty payments and dispositions of undeveloped assets	$37,500
Additional incentive compensation paid	0
Minimum quarterly payment received	37,500
Dr. David M. Goldenberg [Member] | Employment Agreement [Member]	'
Guarantor Obligations [Line Items]	'
Annual base salary	500,000
Percentage of annual bonus target	50.00%
Dr. David M. Goldenberg [Member] | Employment Agreement [Member] | Minimum [Member]	'
Guarantor Obligations [Line Items]	'
Percentage of potential payout target	0.00%
Dr. David M. Goldenberg [Member] | Employment Agreement [Member] | Maximum [Member]	'
Guarantor Obligations [Line Items]	'
Percentage of potential payout target	150.00%
President and Chief Executive Officer [Member]	'
Guarantor Obligations [Line Items]	'
Percentage of increase in annual base salary for next fiscal year	3.50%
President and Chief Executive Officer [Member] | Employment Agreement [Member]	'
Guarantor Obligations [Line Items]	'
Annual base salary	$600,000
Percentage of annual bonus target	50.00%
President and Chief Executive Officer [Member] | Employment Agreement [Member] | Minimum [Member]	'
Guarantor Obligations [Line Items]	'
Percentage of potential payout target	0.00%
President and Chief Executive Officer [Member] | Employment Agreement [Member] | Maximum [Member]	'
Guarantor Obligations [Line Items]	'
Percentage of potential payout target	150.00%
Goldenberg Agreement [Member] | Employment Agreement [Member] | Subsequent Event [Member]	'
Guarantor Obligations [Line Items]	'
Agreement termination date	1-Jul-16
Sullivan Agreement [Member] | Employment Agreement [Member] | Subsequent Event [Member]	'
Guarantor Obligations [Line Items]	'
Agreement termination date	1-Jul-14

Correction_of_Immaterial_Error2

Correction of Immaterial Error - Additional Information (Detail) (USD $)	3 Months Ended
	Sep. 30, 2013	Jun. 30, 2013
Accounts payable and accrued expenses	$3,713,513	$3,950,866
Reduction of deferred tax assets related to net operating losses	1,300,000	'
Adjustment [Member]	'	'
Accounts payable and accrued expenses	'	1,200,000
Overstatement [Member]	'	'
Accounts payable and accrued expenses	'	$3,200,000

Correction_of_Immaterial_Error3

Correction of Immaterial Error - Effect of Recording this Correction in Consolidated Statements of Comprehensive Loss (Detail) (USD $)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Research and development	$7,514,094	$6,793,922
Net loss	-5,226,183	-7,166,817
Net loss attributable to Immunomedics, Inc. stockholders	-5,200,963	-7,140,885
As Reported [Member]	'	'
Research and development	6,653,000	7,035,000
Net loss	-4,365,000	-7,408,000
Net loss attributable to Immunomedics, Inc. stockholders	($4,339,000)	($7,382,000)

Correction_of_Immaterial_Error4

Correction of Immaterial Error - Effect of Recording this Correction in Consolidated Balance Sheet (Detail) (USD $)	Sep. 30, 2013	Jun. 30, 2013
Quantifying Misstatement in Current Year Financial Statements [Line Items]	'	'
Accounts payable and accrued expenses	$3,713,513	$3,950,866
Accumulated deficit	-231,240,775	-226,039,812
Total Immunomedics, Inc. stockholders' equity	36,216,700	40,180,467
As Reported [Member]	'	'
Quantifying Misstatement in Current Year Financial Statements [Line Items]	'	'
Accounts payable and accrued expenses	6,066,000	7,165,000
Accumulated deficit	-233,593,000	-229,254,000
Total Immunomedics, Inc. stockholders' equity	$33,864,000	$36,966,000